Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 45, 2015 - Issue 8
Submit an article Journal homepage
151
Views
3
CrossRef citations to date
0
Altmetric
Animal Pharmacokinetics and Metabolism

Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats

Ala F. NassarDepartment of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA, ;Department of Chemistry, University of Connecticut, Storrs, CT, USA, and Correspondence[email protected]
,
Adam WisnewskiDepartment of Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA,
&
Ivan KingMetastagen, Inc., Wilmington, DE, USA
Pages 711-721 | Received 31 Dec 2014, Accepted 04 Feb 2015, Published online: 23 Mar 2015

References

  • Baumann RP, Seow HA, Shyam K, et al. (2005). The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res 15:313–25
  • Finch RA, Shyam K, Penketh PG, Sartorelli AC. (2001). 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)-carbonylhydrazine (101M): a novel sulfonyl-hydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 61:3033–8
  • Gifford AN, Espaillat MP, Gatley SJ. (2008). Biodistribution of radiolabeled ethanol in rodents. Drug Metab Dispos 36:1853–8
  • Giles F, Thomas D, Garcia-Manero G, et al. (2004). A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10:2908–17
  • Nassar AE, Du J, Lin K, et al. (2010b). Case study: the unanticipated loss of N2 from novel DNA alkylating agent Laromustine by collision-induced dissociation: novel rearrangements [Chapter 5]. Hoboken (NJ): John Wiley & Sons
  • Nassar AE, Du J, Lin K, et al. (2010c). Case study: identification of in vitro metabolite/decomposition products of the novel DNA alkylating agent laromustine [Chapter 6]. Hoboken (NJ): John Wiley & Sons
  • Nassar AE, King I, Paris BL, et al. (2009). An in vitro evaluation of the victim and perpetrator potential of the anti-cancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 (CYP) enzymes. Drug Metab Dispos 37:1922–30
  • Nassar A-EF, Du J, Belcourt M, et al. (2010a). In vitro profiling and mass balance of the anti-cancer agent laromustine [14C]-VNP40101M by rat, dog, monkey and human liver microsomes. Open Drug Metab J 4:1–9
  • Nassar A-EF, King I, Du J. (2011). Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M). Chem Res Toxicol 24:568–78
  • Park YH, Jung BH, Chung BC, et al. (1997). Metabolic disposition of the new fluoroquinolone antibacterial agent DW116 in rats. Drug Metab Dispos 25:1101–3
  • Penketh PG, Shyam K, Baumann RP, et al. (2004). 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): I. Direct inhibition of O6-alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemother Pharmacol 53:279–87
  • Penketh PG, Shyam K, Sartorelli AC. (2000). Comparison of DNA lesions produced by tumor inhibitory 1,2-bis(sulfonyl)-hydrazines and chloroethylnitrosoureas. Biochem Pharmacol 59:283–91
  • Schadt S, Kallbach S, Almeida R, Sandel J. (2012). Investigation of Figopitant and its metabolites in rat tissue by combining whole-body autoradiography with liquid extraction surface analysis mass spectrometry. Drug Metab Dispos 40:419–25
  • Scicinski J, Oronsky B, Taylor M, et al. (2012). Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent. Drug Metab Dispos 40:1810–16
  • Wang L, He K, Maxwell B, et al. (2011). Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos 39:256–64

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.